Your browser doesn't support javascript.
loading
BRAF and NRAS prognostic values in conjunctival melanoma: analysis and literature review.
Valentín-Bravo, Francisco Javier; Pérez-Rodríguez, Álvaro; García-Álvarez, Ciro; García-Lagarto, Elena; Saornil-Álvarez, María Antonia.
Afiliação
  • Valentín-Bravo FJ; Department of Ophthalmology, University Clinical Hospital of Valladolid, Spain.
  • Pérez-Rodríguez Á; Department of Anatomic Pathology, University Hospital of Araba, Vitoria-Gasteiz, Álava, Spain.
  • García-Álvarez C; Department of Ophthalmology, University Clinical Hospital of Valladolid, Spain.
  • García-Lagarto E; Department of Anatomic Pathology, University Clinical Hospital of Valladolid, Spain.
  • Saornil-Álvarez MA; Department of Ophthalmology, University Clinical Hospital of Valladolid, Spain.
Arq Bras Oftalmol ; 86(5): e20230071, 2023.
Article em En | MEDLINE | ID: mdl-35544941
PURPOSE: Conjunctival melanoma is a rare and aggressive tumor with a propensity for regional and distant metastases. This study aimed to analyze BRAF/NRAS markers in conjunctival melanoma and their relationship with tumor recurrences and patient prognosis. METHODS: This retrospective, observational, single-center study included consecutive patients with an anatomopathological diagnosis of conjunctival melanoma, registered between January 1992 and December 2019. BRAF/NRAS mutations were analyzed using cobas®4800 kit (Roche®) in samples obtained by excisional or map biopsy. Additionally, the presence of other associated precancerous or tumor lesions was assessed. RESULTS: A total of 12 patients with positive histological samples for conjunctival melanoma were included (7 women, 5 men), with a mean age at diagnosis of 60 years and a mean evolution time of 6.38 ± 3.4 years. BRAF V600E mutation was observed in three biopsies (25%), similar to NRAS Q61X (25%). Recurrences occurred in all patients with positive BRAF or NRAS mutation, and five of these patients developed systemic dissemination (83.33%). Moreover, four of six patients with mutated BRAF or NRAS (66.66%) had histopathological findings of tumor or precancerous lesions. CONCLUSIONS: BRAF and NRAS mutations may be risk factors for recurrence and shorter survival in conjunctival melanoma, which would make these patients candidates for targeted therapies and comprehensive and individualized follow-up. All these data warrant standardized prospective studies.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Neoplasias Ósseas / Neoplasias da Túnica Conjuntiva / Melanoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans / Male Idioma: En Revista: Arq Bras Oftalmol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Neoplasias Ósseas / Neoplasias da Túnica Conjuntiva / Melanoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans / Male Idioma: En Revista: Arq Bras Oftalmol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha País de publicação: Brasil